NCT06620523 Prevent Cardiac Surgery Associated AKI Trial
| NCT ID | NCT06620523 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | George Washington University |
| Condition | Renal Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 242 participants |
| Start Date | 2024-07-18 |
| Primary Completion | 2027-06-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 242 participants in total. It began in 2024-07-18 with a primary completion date of 2027-06-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Eligibility Criteria
Inclusion Criteria: * Adult 18-70 years of age * Undergoing elective CPB (Cardiopulmonary Bypass) surgery * Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min Exclusion Criteria: * GFR (Glomerular Filtration Rate) \<45 ml/min * Solitary kidney * Status post-kidney transplant * Pregnant women * Allergy to CoQ10 * Allergy to Glutathione * Allergy to Cellulose
Contact & Investigator
Yoosif Abdalla, MD
PRINCIPAL INVESTIGATOR
George Washington University
Frequently Asked Questions
Who can join the NCT06620523 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Renal Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06620523 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06620523 currently recruiting?
Yes, NCT06620523 is actively recruiting participants. Contact the research team at eshaykhinurov@mfa.gwu.edu for enrollment information.
Where is the NCT06620523 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT06620523 clinical trial?
NCT06620523 is sponsored by George Washington University. The principal investigator is Yoosif Abdalla, MD at George Washington University. The trial plans to enroll 242 participants.